Innova Captab Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tag9mocmima367domklpsuzg.pdf

Key Takeaways


Jammu Facility Ramp-Up


Margin Trajectory & Cost Structure

Lohariwala: “So what happened in the initial strategy, that is a capitalized cost. So let's say, if we are putting some plant in the next financial year, then the cost of interest is again capitalized. So directly, it will not flow to the P&L. And that's why we are expecting that there is a margin expansion can happen.”

CDMO Business


Branded Generics & Exports


Product Pipeline & Strategic Bets

Lohariwala: “So we will not be -- as the product is already launched, we will -- we are not in the race of the initial launching and all that. So we will be ready with the wave 2 type concept.”

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthConfident in ability to deliver 20%+ revenue growthFY27
EBITDA growthExpected to outperform revenue growth as Jammu utilization rampsFY27
PAT growthExpected to outpace EBITDA growth, aided by fixed depreciation and interest already in baseFY27
Margin expansionEBITDA margin to be better than FY26; a few percentage points improvement expectedFY27
Jammu EBITDA positiveJammu to become EBITDA positive and start covering fixed costsComing quarter (Q1 FY27)
Jammu volume growthConfident of maintaining 20%+ volume growth from FY26 to FY27FY27

Key Metrics

MetricQ4 FY26
Consolidated revenue₹447.8 cr, +42% YoY
CDMO revenue₹314.8 cr, +41% YoY
Branded Generics revenue₹133 cr, +46% YoY
EBITDA₹66.7 cr, +31% YoY; margin 14.9%
PAT₹38.1 cr, +29% YoY
Exports contribution28% of revenue
FY26 consolidated revenue₹1,630 cr, +31% YoY
FY26 CDMO revenue₹1,133 cr, +24% YoY
FY26 Branded Generics revenue₹497 cr, +51% YoY
FY26 EBITDA₹250.3 cr, margin 15.4%
FY26 PAT₹140.9 cr, +10% YoY
FY26 exports contribution31% of revenue
Jammu facility FY26 revenue₹300 cr
Jammu facility Q4 exit run-rate₹90 cr+
Sharon Bio FY26 revenue~₹240 cr
FY27 volume growth guidance20%+ over FY26
New Baddi plant capex (planned)₹150–170 cr
New Baddi plant revenue potential₹450–500 cr at optimum
Customer base350+ clients
Branded Generics domestic/export split~70% domestic, 30–35% exports
Ex-Jammu EBITDA margin~18–18.2% (per an analyst's math)